Your browser is no longer supported. Please, upgrade your browser.
CORT [NASD]
Corcept Therapeutics Incorporated
Index- P/E25.89 EPS (ttm)0.79 Insider Own3.40% Shs Outstand116.82M Perf Week-7.92%
Market Cap2.45B Forward P/E19.66 EPS next Y1.04 Insider Trans-5.59% Shs Float100.45M Perf Month-8.83%
Income99.40M PEG- EPS next Q0.18 Inst Own73.00% Short Float10.00% Perf Quarter-30.96%
Sales340.10M P/S7.22 EPS this Y11.10% Inst Trans-0.41% Short Ratio18.08 Perf Half Y13.05%
Book/sh4.37 P/B4.68 EPS next Y20.51% ROA18.40% Target Price27.00 Perf Year48.94%
Cash/sh3.11 P/C6.58 EPS next 5Y- ROE20.10% 52W Range12.20 - 31.18 Perf YTD-21.83%
Dividend- P/FCF17.18 EPS past 5Y74.60% ROI19.60% 52W High-34.35% Beta0.72
Dividend %- Quick Ratio10.00 Sales past 5Y47.70% Gross Margin98.50% 52W Low67.79% ATR0.89
Employees236 Current Ratio10.10 Sales Q/Q-14.80% Oper. Margin32.40% RSI (14)30.34 Volatility5.58% 3.80%
OptionableYes Debt/Eq0.00 EPS Q/Q-26.40% Profit Margin29.20% Rel Volume1.25 Prev Close20.45
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout0.00% Avg Volume555.90K Price20.47
Recom2.50 SMA20-9.61% SMA50-13.45% SMA200-5.99% Volume319,809 Change0.10%
Aug-05-20Downgrade Jefferies Buy → Hold $16
Sep-24-19Initiated Jefferies Buy $20
Sep-06-19Initiated H.C. Wainwright Buy $18
Feb-04-19Downgrade B. Riley FBR Buy → Neutral $22 → $12
Aug-10-18Reiterated Stifel Hold $20 → $11
May-31-18Downgrade Stifel Buy → Hold $20
Mar-09-18Initiated B. Riley FBR, Inc. Buy $30
Aug-31-17Initiated Stifel Buy $20
Feb-02-17Initiated Ladenburg Thalmann Buy $14
Apr-21-15Initiated FBR Capital Outperform $12
Jan-13-14Downgrade Stifel Buy → Hold
Aug-09-13Downgrade Ladenburg Thalmann Buy → Neutral $3.30
Aug-09-13Downgrade Janney Buy → Neutral
Feb-21-12Reiterated JMP Securities Mkt Outperform $9 → $11
Jan-06-10Upgrade Ladenburg Thalmann Neutral → Buy $4
Jul-17-08Initiated Rodman & Renshaw Mkt Outperform $8
Jun-21-07Upgrade Punk, Ziegel & Co Mkt Perform → Accumulate
May-07-21 12:17PM  
10:09AM  
06:56AM  
06:31AM  
May-06-21 05:20PM  
04:10PM  
04:05PM  
04:01PM  
02:45PM  
May-05-21 06:32AM  
Apr-29-21 04:05PM  
Apr-26-21 12:31PM  
Apr-05-21 02:42AM  
Mar-25-21 11:30AM  
Mar-24-21 06:12AM  
Mar-16-21 09:34AM  
Mar-15-21 07:30AM  
Mar-01-21 04:05PM  
Feb-23-21 04:05PM  
Feb-19-21 01:26AM  
Feb-14-21 01:32PM  
Feb-10-21 11:40AM  
Feb-09-21 09:54AM  
Feb-08-21 11:00PM  
04:05PM  
03:15PM  
Feb-05-21 08:36AM  
Feb-01-21 04:05PM  
Jan-20-21 12:05AM  
Dec-31-20 09:40AM  
Dec-21-20 12:20AM  
Dec-19-20 06:23PM  
Dec-03-20 11:30AM  
Nov-23-20 05:00PM  
Nov-18-20 05:40PM  
Nov-13-20 05:36AM  
Nov-05-20 10:53AM  
Nov-04-20 12:08PM  
Nov-03-20 05:15PM  
04:29PM  
04:05PM  
03:15PM  
Oct-27-20 04:05PM  
Oct-16-20 08:00AM  
Oct-07-20 10:26AM  
Oct-05-20 12:46PM  
Sep-29-20 09:00AM  
Sep-24-20 07:10AM  
Sep-18-20 07:26AM  
Sep-17-20 10:56AM  
Sep-10-20 08:30AM  
Sep-08-20 04:34AM  
Sep-04-20 11:41AM  
07:04AM  
Sep-03-20 11:31AM  
09:50AM  
08:44AM  
06:31AM  
Sep-01-20 09:34AM  
Aug-05-20 05:56PM  
02:11PM  
02:01AM  
Aug-04-20 04:05PM  
Aug-03-20 06:27PM  
01:00PM  
11:26AM  
Jul-28-20 04:05PM  
08:30AM  
Jul-23-20 08:30AM  
Jul-21-20 07:08PM  
Jul-07-20 10:00AM  
Jul-06-20 12:56PM  
Jul-01-20 10:47AM  
Jun-30-20 04:05PM  
Jun-19-20 09:40AM  
Jun-15-20 08:30AM  
Jun-08-20 11:24PM  
Jun-03-20 11:30AM  
11:30AM  
May-18-20 06:23AM  
May-14-20 04:05PM  
May-13-20 01:16PM  
May-12-20 07:45AM  
May-10-20 10:46PM  
May-06-20 06:27PM  
May-05-20 02:50PM  
08:31AM  
01:02AM  
May-04-20 07:05PM  
04:05PM  
Apr-27-20 04:05PM  
12:00PM  
Apr-22-20 06:43AM  
Apr-13-20 08:31AM  
Apr-02-20 09:51AM  
Apr-01-20 08:30AM  
Mar-26-20 12:06PM  
Mar-21-20 11:30AM  
Mar-12-20 08:30AM  
Feb-25-20 06:22AM  
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Robb Gary CharlesChief Financial OfficerApr 23Sale24.0210,000240,21975,638Apr 27 06:30 PM
WILSON JAMES NDirectorApr 14Option Exercise4.42200,000884,000200,000Apr 16 09:08 PM
Swisher Daniel N JRDirectorApr 05Option Exercise6.557,50049,1257,500Apr 07 05:20 PM
Swisher Daniel N JRDirectorApr 05Sale24.147,500181,0360Apr 07 05:20 PM
Lyon Joseph DouglasChief Accounting OfficerApr 01Option Exercise11.3525,000283,75025,000Apr 05 05:12 PM
Lyon Joseph DouglasChief Accounting OfficerApr 01Sale23.8825,000597,0300Apr 05 05:12 PM
Lyon Joseph DouglasChief Accounting OfficerMar 01Option Exercise8.2725,000206,75025,000Mar 03 05:38 PM
Lyon Joseph DouglasChief Accounting OfficerMar 01Sale25.2125,000630,3200Mar 03 05:38 PM
Maduck SeanSee RemarksFeb 16Option Exercise3.298,98929,57439,013Feb 16 08:50 PM
Maduck SeanSee RemarksFeb 16Sale28.258,989253,90330,024Feb 16 08:50 PM
Robb Gary CharlesChief Financial OfficerFeb 12Sale28.22112,1003,163,89985,638Feb 16 08:15 PM
Maduck SeanSee RemarksFeb 11Option Exercise3.293,40011,18633,424Feb 16 08:50 PM
Maduck SeanSee RemarksFeb 11Sale29.783,400101,24930,024Feb 16 08:50 PM
Robb Gary CharlesChief Financial OfficerFeb 11Sale29.783,400101,249197,738Feb 16 08:15 PM
Lyon Joseph DouglasChief Accounting OfficerFeb 03Option Exercise8.2725,000206,75025,000Feb 04 07:13 PM
Lyon Joseph DouglasChief Accounting OfficerFeb 03Sale29.1825,000729,5700Feb 04 07:13 PM
Robb Gary CharlesChief Financial OfficerJan 22Option Exercise2.70451,8521,220,000459,877Jan 26 09:35 PM
BELANOFF JOSEPH KChief Executive OfficerJan 22Option Exercise4.42800,0003,536,0003,299,214Jan 26 09:33 PM
Swisher Daniel N JRDirectorJan 19Option Exercise6.555,00032,7505,000Jan 21 05:05 PM
Swisher Daniel N JRDirectorJan 19Sale28.745,000143,6860Jan 21 05:05 PM
Lyon Joseph DouglasChief Accounting OfficerJan 04Option Exercise8.2725,000206,75025,000Jan 04 07:43 PM
Lyon Joseph DouglasChief Accounting OfficerJan 04Sale26.1325,000653,3450Jan 04 07:43 PM
Lyon Joseph DouglasChief Accounting OfficerDec 30Option Exercise7.5425,000188,45725,000Jan 04 07:43 PM
Lyon Joseph DouglasChief Accounting OfficerDec 30Sale26.0725,000651,7520Jan 04 07:43 PM
BAKER G LEONARD JRDirectorDec 01Buy22.64681,5403,208,303Dec 02 07:41 PM
BAKER G LEONARD JRDirectorNov 30Buy22.801,10925,2853,208,235Dec 02 07:41 PM
BAKER G LEONARD JRDirectorNov 25Buy22.813618,2333,207,126Nov 30 07:46 PM
Hunt HazelChief Scientific OfficerNov 24Option Exercise3.9650,000198,00050,200Nov 27 04:08 PM
BAKER G LEONARD JRDirectorNov 24Buy22.931,42932,7663,206,765Nov 24 08:06 PM
BAKER G LEONARD JRDirectorNov 23Buy22.931,55135,5623,205,336Nov 24 08:06 PM
BAKER G LEONARD JRDirectorNov 18Buy17.912,37242,4913,203,785Nov 19 07:48 PM
BAKER G LEONARD JRDirectorNov 17Buy17.827,883140,4693,201,413Nov 17 07:43 PM
BAKER G LEONARD JRDirectorNov 13Buy17.942003,5883,193,530Nov 17 07:43 PM
BAKER G LEONARD JRDirectorNov 10Buy17.7115,000265,6353,193,330Nov 12 06:07 PM
BAKER G LEONARD JRDirectorNov 09Buy17.963,78668,0133,178,330Nov 12 06:07 PM
BAKER G LEONARD JRDirectorNov 06Buy17.9813,500242,6653,174,544Nov 10 08:21 PM
Swisher Daniel N JRDirectorOct 19Option Exercise6.555,00032,7505,000Oct 21 09:08 PM
Swisher Daniel N JRDirectorOct 19Sale17.665,00088,3010Oct 21 09:08 PM
BAKER G LEONARD JRDirectorSep 01Buy12.5025,807322,5263,161,044Sep 01 08:26 PM
BAKER G LEONARD JRDirectorAug 28Buy12.4820,444255,2133,135,237Sep 01 08:26 PM
Swisher Daniel N JRDirectorJul 17Option Exercise6.555,00032,7505,000Jul 20 07:14 PM
Swisher Daniel N JRDirectorJul 17Sale16.485,00082,4110Jul 20 07:14 PM
BAKER G LEONARD JRDirectorMay 28Option Exercise3.4730,000104,1001,026,838May 29 04:09 PM
BAKER G LEONARD JRDirectorMay 28Sale15.7030,000471,060996,838May 29 04:09 PM
Swisher Daniel N JRDirectorMay 22Option Exercise6.555,00032,7505,000May 27 07:53 PM
MAHONEY DAVID LDirectorMay 22Option Exercise3.4738,984135,27488,984May 27 07:48 PM
Swisher Daniel N JRDirectorMay 22Sale16.105,00080,5000May 27 07:53 PM